{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:26:44Z","timestamp":1793831204176,"version":"4.6.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T00:00:00Z","timestamp":1791676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010623","name":"University of Thessaly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010623","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.autrev.2026.104195","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T22:52:58Z","timestamp":1791672778000},"page":"104195","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Functional characterization of genetic variants associated with response to tumor necrosis factor inhibitors in psoriatic arthritis patients"],"prefix":"10.1016","volume":"26","author":[{"given":"Angeliki","family":"Planaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Simopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Themistoklis","family":"Giannoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efterpi","family":"Zafiriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios P.","family":"Bogdanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theologia","family":"Sarafidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalliopi","family":"Liadaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2026.104195_bb0005","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-021-00293-y","article-title":"Psoriatic arthritis","volume":"7","author":"FitzGerald","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.autrev.2026.104195_bb0010","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","article-title":"Group for Research and Assessment of psoriasis and psoriatic arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021","volume":"18","author":"Coates","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2026.104195_bb0015","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1136\/ard-2024-225531","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update","volume":"83","author":"Gossec","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104195_bb0020","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/path.2287","article-title":"TNF-mediated inflammatory disease","volume":"214","author":"Bradley","year":"2008","journal-title":"J Pathol"},{"key":"10.1016\/j.autrev.2026.104195_bb0025","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/j.rdc.2015.07.010","article-title":"Biologic therapy for psoriatic arthritis","volume":"41","author":"Mease","year":"2015","journal-title":"Rheum Dis Clin N Am"},{"key":"10.1016\/j.autrev.2026.104195_bb0030","series-title":"Fc receptors in immune responses. Reference module in Biomedical Sciences","author":"Mancardi","year":"2014"},{"key":"10.1016\/j.autrev.2026.104195_bb0035","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1136\/ard-2024-225534","article-title":"Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"83","author":"Kerschbaumer","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104195_bb0040","doi-asserted-by":"crossref","unstructured":"Firdous S, Amjad H, Choudhary MU, Afzal MW, Tayyab RH, Parveen A. Emerging biological therapies for psoriatic arthritis: a systematic review. Medicine 2025; 104, e45259. doi.org\/https:\/\/doi.org\/10.1097\/MD.0000000000045259.","DOI":"10.1097\/MD.0000000000045259"},{"key":"10.1016\/j.autrev.2026.104195_bb0045","doi-asserted-by":"crossref","first-page":"518","DOI":"10.3109\/03009741003781969","article-title":"Association between the FCGR3AV158F polymorphism and the clinical response to infliximab in rheumatoid arthritis and spondyloarthritis patients","volume":"39","author":"Morales-Lara","year":"2010","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2026.104195_bb0050","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jbspin.2012.02.003","article-title":"Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis","volume":"79","author":"Morales-Lara","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.autrev.2026.104195_bb0055","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.3899\/jrheum.110980","article-title":"FCGR2A\/CD32AandFCGR3A\/CD16AVariants and EULAR response to tumor necrosis factor-\u03b1 blockers in psoriatic arthritis: a longitudinal study with 6 months of followup","volume":"39","author":"Ram\u00edrez","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2026.104195_bb0060","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1038\/jid.2014.123","article-title":"TNF-\u03b1 gene polymorphisms: association with disease susceptibility and response to anti-TNF-\u03b1 treatment in psoriatic arthritis","volume":"134","author":"Murdaca","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2026.104195_bb0065","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1111\/jdv.15431","article-title":"Polymorphisms associated with anti-TNF drugs response in patients with psoriasis and psoriatic arthritis","volume":"33","author":"Ovejero-Benito","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.autrev.2026.104195_bb0070","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.2217\/pgs.14.125","article-title":"PDE3A-SLCO1C1 locus is associated with response to anti-tumor necrosis factor therapy in psoriatic arthritis","volume":"15","author":"Juli\u00e0","year":"2014","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.autrev.2026.104195_bb0075","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11926-015-0518-z","article-title":"Pharmacogenetics of treatment response in psoriatic arthritis","volume":"17","author":"Jani","year":"2015","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2026.104195_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25115793","article-title":"The association between genetics and response to treatment with biologics in patients with psoriasis, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases: a systematic review and meta-analysis","volume":"25","author":"Al-Sofi","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.autrev.2026.104195_bb0085","first-page":"1","article-title":"Do genetics contribute to TNF inhibitor response prediction in Psoriatic Arthritis?","volume":"23","author":"Curry","year":"2023","journal-title":"Pharm J"},{"key":"10.1016\/j.autrev.2026.104195_bb0090","doi-asserted-by":"crossref","first-page":"943","DOI":"10.2217\/pgs.16.20","article-title":"Pharmacogenomics of multifactorial diseases: a focus on psoriatic arthritis","volume":"17","author":"Cascella","year":"2016","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.autrev.2026.104195_bb0095","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/FPC.0b013e3283544043","article-title":"Investigation of single nucleotide polymorphisms and biological pathways associated with response to TNFa inhibitors in patients with rheumatoid arthritis","volume":"22","author":"Krintel","year":"2012","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.autrev.2026.104195_bb0100","doi-asserted-by":"crossref","first-page":"727","DOI":"10.2217\/pgs.13.60","article-title":"GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis","volume":"14","author":"Acosta-Colman","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.autrev.2026.104195_bb0105","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1093\/rheumatology\/kel175","article-title":"The \u2212308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients","volume":"46","author":"Seitz","year":"2007","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2026.104195_bb0110","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.2217\/pgs.15.90","article-title":"Association between TNF-a (\u2212308 a\/G, \u2212238 A\/G, \u2212857 C\/T) polymorphisms and responsiveness to TNF-a blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis","volume":"16","author":"Song","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.autrev.2026.104195_bb0115","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1136\/annrheumdis-2015-eular.3082","article-title":"The TNF alpha-308 and the IL-6 -174 promoter polymorphisms associate with effective anti-TNF alpha treatment in seronegative spondyloarthritis","volume":"74","author":"Fabris","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104195_bb0120","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2007-01-070656","article-title":"Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V\/V and V\/F polymorphism","volume":"110","author":"Hatjiharissi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2026.104195_bb0125","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood.V90.3.1109","article-title":"Fc gammaRIIIa-158V\/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L\/R\/H phenotype","volume":"90","author":"Koene","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2026.104195_bb0130","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.4049\/jimmunol.147.4.1338","article-title":"A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding","volume":"147","author":"Warmerdam","year":"1991","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2026.104195_bb0135","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1172\/JCI116022","article-title":"On the interaction of IgG subclasses with the low affinity Fc gamma RIIa (CD32) on human monocytes, neutrophils, and platelets. Analysis of a functional polymorphism to human IgG2","volume":"90","author":"Parren","year":"1992","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2026.104195_bb0140","doi-asserted-by":"crossref","unstructured":"The GTEx Consortium. The GTEx consortium atlas of genetic regulatory effects across human tissues. Science 2020;369:1318\u20131330. doi.org\/https:\/\/doi.org\/10.1126\/science.aaz1776.","DOI":"10.1126\/science.aaz1776"},{"key":"10.1016\/j.autrev.2026.104195_bb0145","doi-asserted-by":"crossref","first-page":"D930","DOI":"10.1093\/nar\/gkr917","article-title":"HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants","volume":"40","author":"Ward","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.autrev.2026.104195_bb0150","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1101\/gr.137323.112","article-title":"Annotation of functional variation in personal genomes using RegulomeDB","volume":"22","author":"Boyle","year":"2012","journal-title":"Genome Res"},{"key":"10.1016\/j.autrev.2026.104195_bb0155","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1152\/physrev.00045.2017","article-title":"The TNF family of ligands and receptors: communication modules in the immune system and beyond","volume":"99","author":"Dostert","year":"2019","journal-title":"Physiol Rev"},{"key":"10.1016\/j.autrev.2026.104195_bb0160","doi-asserted-by":"crossref","first-page":"D933","DOI":"10.1093\/nar\/gkac958","article-title":"Ensembl 2023","volume":"51","author":"Martin","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.autrev.2026.104195_bb0165","first-page":"5114","article-title":"Alternative splicing regulation in tumor necrosis factor-mediated inflammation","volume":"14","author":"L\u00f3pez-Urrutia","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.autrev.2026.104195_bb0170","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/nature11307","article-title":"TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis","volume":"488","author":"Gregory","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.autrev.2026.104195_bb0175","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1136\/annrheumdis-2012-203023","article-title":"Identification of a new exon 2-skipped TNFR1 transcript: regulation by three functional polymorphisms of the TNFR-associated periodic syndrome (TRAPS) gene","volume":"73","author":"Rittore","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2026.104195_bb0180","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/cdd.2014.81","article-title":"Getting TRAIL back on track for cancer therapy","volume":"21","author":"Lemke","year":"2014","journal-title":"Cell Death Differ"},{"key":"10.1016\/j.autrev.2026.104195_bb0185","first-page":"1688","article-title":"Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer","volume":"7","author":"Fisher","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.autrev.2026.104195_bb0190","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1093\/rheumatology\/kel108","article-title":"Tumour necrosis factor-related apoptosis-inducing ligand and osteoprotegerin serum levels in psoriatic arthritis","volume":"45","author":"Hofbauer","year":"2006","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2026.104195_bb0195","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/sj.gene.6363747","article-title":"Allele-specific quantification of tumor necrosis factor alpha (TNF) transcription and the role of promoter polymorphisms in rheumatoid arthritis patients and healthy individuals","volume":"2","author":"Kaijzel","year":"2001","journal-title":"Genes Immun"},{"key":"10.1016\/j.autrev.2026.104195_bb0200","article-title":"Correlation between TNF -308 and +489 gene polymorphism and acute exacerbation of chronic obstructive pulmonary diseases","volume":"2021","author":"Yu","year":"2021","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.autrev.2026.104195_bb0205","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/9743037","article-title":"lncRNA IGHC\u03b31 acts as a ceRNA to regulate macrophage inflammation via the miR-6891-3p\/TLR4 axis in osteoarthritis","volume":"2020","author":"Zhang","year":"2020","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.autrev.2026.104195_bb0210","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1007\/s00018-013-1522-y","article-title":"BAG-6, a jack of all trades in health and disease","volume":"71","author":"Binici","year":"2013","journal-title":"Cell Mol Life Sci"},{"key":"10.1016\/j.autrev.2026.104195_bb0215","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41467-021-27850-z","article-title":"A genome-wide association study of serum proteins reveals shared loci with common diseases","volume":"13","author":"Gudjonsson","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2026.104195_bb0220","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/hmg\/ddm377","article-title":"The PSORS1 locus gene CCHCR1 affects keratinocyte proliferation in transgenic mice","volume":"17","author":"Tiala","year":"2008","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.autrev.2026.104195_bb0225","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.amjms.2017.01.019","article-title":"AP-1 expression and its clinical relevance in immune disorders and cancer","volume":"353","author":"Trop-Steinberg","year":"2017","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.autrev.2026.104195_bb0230","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jaut.2016.10.008","article-title":"A critical role of transcription factor YY1 in rheumatoid arthritis by regulation of interleukin-6","volume":"77","author":"Lin","year":"2017","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2026.104195_bb0235","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202255326","article-title":"The transcriptional regulator Sin3A balances IL-17A and Foxp3 expression in primary CD4 T cells","volume":"24","author":"Perucho","year":"2023","journal-title":"EMBO Rep"},{"key":"10.1016\/j.autrev.2026.104195_bb0240","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a036418","article-title":"A20 at the crossroads of cell death, inflammation, and autoimmunity","volume":"12","author":"Martens","year":"2020","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.autrev.2026.104195_bb0245","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/jid.2011.376","article-title":"TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis","volume":"132","author":"Tejasvi","year":"2012","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2026.104195_bb0250","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jid.2018.11.033","article-title":"WAKMAR2, a long noncoding RNA downregulated in human chronic wounds, modulates keratinocyte motility and production of inflammatory chemokines","volume":"139","author":"Herter","year":"2019","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.autrev.2026.104195_bb0255","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a041230","article-title":"Beyond the code: noncoding RNAs in skin wound healing","volume":"14","author":"Li","year":"2022","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.autrev.2026.104195_bb0260","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrg.2015.10","article-title":"Unique features of long non-coding RNA biogenesis and function","volume":"17","author":"Quinn","year":"2016","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.autrev.2026.104195_bb0265","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.bbagrm.2015.06.003","article-title":"Long noncoding RNAs: re-writing dogmas of RNA processing and stability","volume":"1859","author":"Wilusz","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.autrev.2026.104195_bb0270","doi-asserted-by":"crossref","first-page":"D1276","DOI":"10.1093\/nar\/gkaa783","article-title":"miRNASNP-v3: a comprehensive database for SNPs and disease-related variations in miRNAs and miRNA targets","volume":"49","author":"Liu","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.autrev.2026.104195_bb0275","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/cas.12499","article-title":"miR-639 regulates transforming growth factor beta-induced epithelial\u2013mesenchymal transition in human tongue cancer cells by targeting FOXC1","volume":"105","author":"Lin","year":"2014","journal-title":"Cancer Sci"},{"key":"10.1016\/j.autrev.2026.104195_bb0280","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2025.157078","article-title":"FOXC1 ameliorates the disease progression of psoriasis through transcriptional upregulation of SOCS3","volume":"197","author":"Duan","year":"2026","journal-title":"Cytokine"},{"issue":"12","key":"10.1016\/j.autrev.2026.104195_bb0285","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/ng.2462","article-title":"High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis","volume":"44","author":"Eyre","year":"2012","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.autrev.2026.104195_bb0290","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/ng.3359","article-title":"Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations","volume":"47","author":"Liu","year":"2015","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.autrev.2026.104195_bb0295","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/ng.764","article-title":"Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47","volume":"43","author":"Anderson","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.autrev.2026.104195_bb0300","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202012112","article-title":"Resolving mechanisms of immune-mediated disease in primary CD4 T cells","volume":"12","author":"Bourges","year":"2020","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.autrev.2026.104195_bb0305","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1038\/s41467-020-15022-4","article-title":"Prioritizing disease and trait causal variants at the TNFAIP3 locus using functional and genomic features","volume":"11","author":"Ray","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.autrev.2026.104195_bb0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.114225","article-title":"Single nucleotide polymorphisms in ADAM17, IL23R and SLCO1C1 genes protect against infliximab failure in adults with Crohn's disease","volume":"159","author":"Laserna-Mendieta","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.autrev.2026.104195_bb0315","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00424-003-1168-y","article-title":"Organic anion transporting polypeptides of the OATP\/ SLC21 family: phylogenetic classification as OATP\/ SLCO superfamily, new nomenclature and molecular\/functional properties","volume":"447","author":"Hagenbuch","year":"2004","journal-title":"Pflugers Arch"},{"key":"10.1016\/j.autrev.2026.104195_bb0320","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.mam.2012.10.009","article-title":"The slco (former slc21) superfamily of transporters","volume":"34","author":"Hagenbuch","year":"2013","journal-title":"Mol Asp Med"},{"key":"10.1016\/j.autrev.2026.104195_bb0325","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/nri2818","article-title":"NFAT, immunity and cancer: a transcription factor comes of age","volume":"10","author":"M\u00fcller","year":"2010","journal-title":"Nat Rev Immunol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226002090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997226002090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:16:32Z","timestamp":1793830592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997226002090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2027,1]]}},"alternative-id":["S1568997226002090"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104195","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Functional characterization of genetic variants associated with response to tumor necrosis factor inhibitors in psoriatic arthritis patients","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2026.104195","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"104195"}}